Health Care/Hospital

First Patient Enrolled in the US Phase 2 Combination Therapy of Akeso's Ligufalimab with Azacitidine for Myelodysplastic Syndrome

HONG KONG, Aug. 6, 2024 /PRNewswire/ -- Akeso has announced the completion of the first patient enrollment in the US for the phase II clinical trial of its innovative CD47 monoclonal antibody, ligufalimab (AK117), in combination with azacitidine for patients with newly diagnosed higher-risk myelo...

2024-08-06 12:44 1655

OBiO Technology Congratulates on The First Clinical Gene Editing Therapy to Treat An Overseas Patient in China by CorrectSequence Therapeutics

SHANGHAI, Aug. 5, 2024 /PRNewswire/ -- Recently, CorrectSequence Therapeutics Co., Ltd. (Correctseq) announced a significant milestone in their base editing therapy CS-101 for transfusion-dependent β-thalassemia. Utilizing their pioneering transformer Base Editor (tBE), Correctseq has successfull...

2024-08-06 11:01 1771

META Pharmaceuticals announces FDA Grants Rare Pediatric Disease Designation to META-001-PH for the Treatment of Primary Hyperoxaluria

HONG KONG, Aug. 5, 2024 /PRNewswire/ -- META Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation (RPDD) to its investigational new drug META-001-PH for the treatment of primary hyperoxaluria (PH).Primary hyperoxaluria is a...

2024-08-05 21:52 1895

Antennova Announces CD73 Small Molecule Inhibitor Accepted for Mini Oral Presentation at ESMO Congress 2024

BOSTON, Aug. 5, 2024 /PRNewswire/ -- Antennova, a clinical-stage biotech company focused on oncology today announced that the orally administered CD73 small molecule inhibitor ATN-037(also known as ATG-037) has been accepted for Mini Oral presentation at the 2024 European Society of Medical Oncol...

2024-08-05 20:00 1584

QBIOTICS WELCOMES STEPHEN DOYLE AS CHIEF EXECUTIVE OFFICER

* Stephen Doyle has more than 24 years of experience in the global pharmaceutical industry, including leadership positions with companies such as Sanofi Aventis and Boehringer Ingelheim. He was most recently Chief Business Officer at Aslan Pharmaceuticals. * Mr Doyle brings extensive knowledg...

2024-08-05 19:00 1937

So-Young to Report Second Quarter 2024 Financial Results on August 23, 2024

BEIJING, Aug. 5, 2024 /PRNewswire/ -- So-Young International Inc. (NASDAQ: SY) ("So-Young" or the "Company"), the largest and most vibrant social community in China for consumers, professionals and service providers in the medical aesthetics industry, today announced that it will report its financ...

2024-08-05 17:00 2547

Formosa Pharmaceuticals Announces Licensing Agreement with Apotex Inc., for Commercialization of Clobetasol Propionate Ophthalmic Suspension for Ocular Surgery Relief and Recovery

TAIPEI, Aug. 5, 2024 /PRNewswire/ -- Taiwan-based Formosa Pharmaceuticals (" Formosa", 6838.TWO) announced today that the company has entered into an exclusive licensing agreement with Apotex Inc. ("Apotex"), for exclusive rights inCanada to the commercialization of clobetasol propionate ophthalmi...

2024-08-05 16:30 1674

INAUGURAL NUHS SCIENTIFIC & INNOVATION SUMMIT CHAMPIONS PREDICTIVE, PRECISE AND PERSONALISED CARE

From digital twin technology to leveraging AI in tackling obesity, the NUHS Scientific & Innovation Summit is a congregation of the brightest minds in cutting-edge medicine – with patients' utmost care at heart SINGAPORE, Aug. 3, 2024 /PRNewswire/ -- Hepatocellular carcinoma (HCC) is one of the ...

2024-08-03 14:02 3681

Latest Updates on the 7th China International Import Expo Unveiled

SHANGHAI, Aug. 2, 2024 /PRNewswire/ -- With less than 100 days to go, the curtains have been drawn on the latest updates for the 7th China International Import Expo (CIIE), which is set to be held from November 5th to 10th, 2024, Shanghai. Preparations for the event are on track, with substantial...

2024-08-02 12:26 2008

Novel Non-Covalent Hits Against GPX4 Identified Using the RiDYMO® Reinforced Dynamics Platform of DP Technology

Research on ferroptosis is gaining momentum, but the development of small molecule inhibitors faces numerous challenges BEIJING, Aug. 1, 2024 /PRNewswire/ -- Glutathione peroxidase 4 (GPX4) is recognized as a critical regulator of ferroptosis, playing a significant role in lipid and amino acid m...

2024-08-01 17:00 1828

MGI Tech Partners with UNALM and Inca Tops to Enhance Alpaca Fiber and Strengthen Peru's Textile Industry

* A genetic sequencing project involving 1,500 alpacas from Puno aims to refine the quality and fineness of their fiber. * The adoption of genomics in the alpaca industry offers many advantages, such as enhancing the quality of alpaca fiber and promoting the growth of thousands of producers i...

2024-08-01 15:47 1705

WuXi Biologics' Four Manufacturing Facilities and Biosafety Testing Center Certified Again by European Medicines Agency for Ten Biologics

WUXI and SUZHOU, China, Aug. 1, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced that four manufacturing facilities and Suzhou Biosafety Testing Center inChina have received Good Ma...

2024-08-01 15:00 2774

Medicilon and Hengrui Pharma Deepen Strategic Collaboration to Support Innovation in ADCs, Small Nucleic Acids, and CGT Drugs

BOSTON, July 31, 2024 /PRNewswire/ -- Recently, Shanghai Medicilon Inc. ("Medicilon") and Jiangsu Hengrui Pharmaceuticals Co., Ltd. ("Hengrui Pharma") reached a strategic collaboration agreement.The cooperative efforts will focus on preclinical evaluation of new drug modalities, particularly ADCs...

2024-07-31 22:39 1444

SURGLASSES Announces Successful First Clinical Implementation of Caduceus S AR Surgical Navigation System in Thailand

ONTARIO, Calif., July 31, 2024 /PRNewswire/ -- Leading augmented reality (AR) medical technology company SURGLASSES today announced that, in collaboration with exclusive distributor Goodlifeintertrade.co. Ltd., it has successfully registered and clinically implemented its AR-based Caduceus S surg...

2024-07-31 21:00 2196

JelloX Biotech collaborates with Mayo Clinic to develop AI enhanced 3D pathology imaging technology

HSINCHU, July 31, 2024 /PRNewswire/ -- JelloX Biotech Inc. ('JelloX') is pleased to announce that it has entered into a collaboration through a know-how agreement with Mayo Clinic to further develop and validate their 3D digital imaging and AI analysis technology. JelloX previously participated i...

2024-07-31 17:00 1380

Fapon Delivers Customized IVD Solutions for the US Market at ADLM 2024

CHICAGO, July 31, 2024 /PRNewswire/ -- Fapon, a global leading life sciences company, is showcasing its innovative IVD total solutions at ADLM 2024 (formerly the AACC Annual Scientific Meeting & Clinical Lab Expo), fromJuly 28 to August 1 in Chicago. Committed to supporting local partners, we del...

2024-07-31 14:42 1237

FDA Grants Orphan Drug Designation (ODD) Status to Zymedi's ZMA001 for Pulmonary Arterial Hypertension

INCHEON, South Korea, July 30, 2024 /PRNewswire/ -- Zymedi (CEO Sunghoon Kim) announced that its first-in-class antibody treatment ZMA001, currently in development for pulmonary arterial hypertension (PAH), has been designated as an Orphan Drug by the U.S. Food and Drug Administration (FDA). Pul...

2024-07-31 08:00 1648

Porton Advanced and Geneseed Biotech Enter into Strategic Collaboration to Focus on Advancing circRNA Innovative Therapeutics

SUZHOU, China, July 30, 2024 /PRNewswire/ -- On July 29, 2024, Porton Advanced Solutions ("Porton Advanced") announced that it had reached a strategic cooperation with Guangzhou Geneseed Biotech Co., Ltd ("Geneseed Biotech"). Both sides will combine their respective strengths in the field of gene...

2024-07-30 22:00 2387

Baird Medical Announces Engagement and Education Program for the Development of Thyroid Microwave Ablation Technology

FRISCO, Texas, July 30, 2024 /PRNewswire/ -- Baird Medical Devices, Inc. ("Baird Medical"), a leading developer and provider of microwave ablation ("MWA") medical devices inChina and the United States, today announced a cross-market engagement and education program designed at fostering both kno...

2024-07-30 17:00 1689

Synthetica Pioneering Closes a Series A Funding Round to Support Development of Oncolytic Bacterial Therapy for Solid Tumors

SHENZHEN, China, July 30, 2024 /PRNewswire/ -- Shenzhen Synthetica Pioneering Co., Ltd. (Synthetica), a biotech startup specializing in synthetic biology for engineering novel living bacterial therapeutics, has recently closed a Series A funding round, led by Boehringer Ingelheim Venture Fund and...

2024-07-30 14:00 1602
1 ... 19202122232425 ... 277